Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Health Network, Toronto
With
Canadian Institutes of Health Research (CIHR)
University of Toronto
Age
18–any
Sex
FEMALE
Healthy volunteers
Accepted
You may be eligible if
Scheduled to undergo treatment with one of the following regimens: (a) 5-fluorouracil, epirubicin, cyclophosphamide, followed by docetaxel and trastuzumab, (b) adriamycin, cyclophosphamide, followed by docetaxel and trastuzumab, (c) adriamycin-cyclophosphamide with weekly paclitaxel and trastuzumab, or (d) dose dense adriamycin and cyclophosphamide followed by dose dense paclitaxel and trastuzumab
Able to tolerate five \~60 minute CMR examinations over 15 months
Able to give informed consent
You may not be if
Life expectancy \< 12 months
Participating in a clinical trial of a new cancer drug
Having received previous anthracycline
History of myocardial infarction or previous heart failure
Current unstable angina, persistent atrial fibrillation or other irregular rhythm, or a history of more than mild regurgitant or stenotic valvular heart disease
Severely reduced renal function (GFR ≤ 30 milliliters/minute)
General MRI contraindications
Baseline LVEF \<55% by echo
echocardiography image quality inadequate for strain analysis
Clareo Health | Evaluation of Myocardial Changes During BReast Adenocarcinoma Therapy to Detect Cardiotoxicity Earlier With MRI
